A Company Built for Patients.

We are a team of scientists, physicians and entrepreneurs determined to unlock the potential of cannabinoid-based medicines using precision technologies to deliver relief for patients with unmet medical needs.

Executive Management

As CEO of Receptor, Mr. Wesner is responsible for the development and commercialization of products that leverage the company’s patented drug delivery technologies. Mr. Wesner is a leading intellectual property attorney and corporate growth strategist with decades of experience in pharmaceutical and life sciences companies. He has designed and implemented IP-driven strategies to power growth, financing, mergers and acquisitions, and public offerings.

Mr. Wesner identified the potential for immediate onset inhaled dry powder cannabinoid drugs, forging the exclusive Receptor-Mannkind global partnership. He also contributed to developing Receptor’s oral delivery technology that facilitates enhanced bioavailability of orally administered cannabinoid drugs. Receptor has adapted and patented its oral delivery technology for the global cannabinoid market.

Super Lawyer Washington Magazine has recognized Mr. Wesner yearly since 2007, and is recognized by Best Lawyers in America for his intellectual property expertise.

Dr. Devinsky is the Director of the New York University (NYU) Comprehensive Epilepsy Center and the Saint Barnabas Institute of Neurology and Neurosurgery. He is also a Professor of Neurology, Neurosurgery, and Psychiatry at NYU Langone School of Medicine. Dr. Devinsky specializes in epilepsy and behavioral neurology.

He serves as a reviewer for more than 30 journals and is a key member of several Scientific Advisory Boards across the pharmaceutical industry. Dr. Devinsky has published more than 500 articles and book chapters and has led multiple antiepileptic clinical trials. He has current research support from NINDS, NIMH, NIBIB, DoD, MURI, National Science Foundation and Simmons Foundation.

In the field of cutting-edge cannabinoid research, Dr. Devinsky served as a principal investigator for the development of GW Pharmaceuticals' Epidiolex® (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.

Dr. Leone-Bay is an internationally recognized authority on inhaled dry powder and oral drug delivery technologies. She brings unparalleled pharmaceutical development and formulation expertise with 48 publications in peer-reviewed journals and 93 issued U.S. patents.

Formerly Vice President and head of pharmaceutical development for MannKind Corporation, Dr. Leone-Bay has decades of drug development experience. Among her achievements are two FDA-approved and currently marketed products. She is an experienced R&D manager having led corporate divisions dedicated to research, development and commercialization of regulated drug products and drug-device combinations.

Ms. Carman is an experienced finance and operations executive whose strategic insight and expertise led to the financial growth and scalable operations of numerous corporations, non-profits, and startups across a range of industries. Ms. Carman’s track record includes securing several successful funding rounds, IPO financial reporting, and structuring and closing multiple critical financings for startup companies. Ms. Carman has led and scaled all aspects of finance, accounting, tax, FP&A, treasury, risk management, debt and equity financing, and mergers and acquisions.

Board of Directors

As the former President, Starbucks, Mr. Rubinfeld was instrumental in building the company's development from IPO to the Fortune 150. He was responsible for global development, R&D, quality assurance, and regulatory compliance. Known for his leading-edge, visionary work in integrated brand positioning, marketing, and design across corporate divisions and platforms, Mr. Rubinfeld built Starbucks into one of the world's most recognizable brands.

Mr. Rubinfeld has extensive board experience and most recently served as Independent Director for United Capital, which was purchased in July 2019 by Goldman Sachs for $750M. He is Founder of AIRVISION Advisors, a strategic growth advisory firm and co-authored Built for Growth - Expanding Your Business Around the Corner or Across the Globe.

Business Week recognized Mr. Rubinfeld as one of the top "Candidates for the Corner Office" in their "CEOs of Tomorrow."

Mr. Casdin has a proven record of success in healthcare business investments and over 20 years of experience in corporate leadership roles. Mr. Casdin is currently a Board Member of Erasca and DiaVacs and serves on the Advisory Board of Luna DNA. He also previously served as a Board member of Ignyta and Dusa Pharmaceuticals until their respective acquisitions by Roche and Sun Pharma.

Alex's operational leadership roles have included Chief Financial Officer of Sophiris Bio and Vice President, Finance at Amylin Pharamceuticals. Prior to that he founded and ran Casdin Advisors LLC, providing strategic advice to life science companies, including Amylin. Mr. Casdin was Chief Executive Officer and Portfolio Manager of Cooper Hill Partners LLC, a healthcare investment fund.

James B. Weissman, Executive Vice President and Chief Operating Officer, Dicerna Pharmaceuticals. Mr. Weissman has more than 30 years’ experience in the life sciences industry, with extensive international management experience in biotech and pharmaceutical general management, product development, licensing, business development, marketing and M&A activities. At Dicerna, Mr. Weissman leads alliance management, business development, corporate communications, corporate operations, and new product planning.

Prior to Dicerna, Mr. Weissman was vice president of business development at MannKind Corporation, responsible for leading the company’s activities related to licensing, new products and strategic planning. Mr. Weissman held leadership positions in both business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, most recently as senior director of marketing. In that position, he was responsible for the sales, profit and strategic targets for the company’s specialty products, including central nervous system, endocrinology, ophthalmology and oncology therapeutics and diversified portfolios.

Ms. Carman is an experienced finance and operations executive whose strategic insight and expertise led to the financial growth and scalable operations of numerous corporations, non-profits, and startups across a range of industries. Ms. Carman’s track record includes securing several successful funding rounds, pre-IPO financial reporting, and structuring and closing multiple critical financings for startup companies. Ms. Carman has led and scaled all aspects of finance, accounting, tax, FP&A, treasury, risk management, debt and equity financing, and M&A.

As CEO of Receptor, Mr. Wesner is responsible for the development and commercialization of products that leverage the company’s patented drug delivery technologies. Mr. Wesner is a leading intellectual property attorney and corporate growth strategist with decades of experience in pharmaceutical and life sciences companies. He has designed and implemented IP-driven strategies to power growth, financing, mergers and acquisitions, and public offerings.

Mr. Wesner identified the potential for immediate onset inhaled dry powder cannabinoid drugs, forging the exclusive Receptor-Mannkind global partnership. He also contributed to developing Receptor’s oral delivery technology that facilitates enhanced bioavailability of orally administered cannabinoid drugs. Receptor has adapted and patented its oral delivery technology for the global cannabinoid market.

Super Lawyer Washington Magazine has recognized Mr. Wesner yearly since 2007, and is recognized by Best Lawyers in America for his intellectual property expertise.